Drug Profile


Alternative Names: AMG223; ASP1585; ILY-101; Kiklin Capsules

Latest Information Update: 07 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ilypsa
  • Developer Amgen; Astellas Pharma
  • Class Polymers; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Sep 2015 Preregistration for Hyperphosphataemia in Japan (PO; Granules)
  • 01 Apr 2015 Astellas completes a phase III clinical trial in Hyperphosphataemia (in patients with chronic kidney disease not undergoing haemodialysis) in Japan (NCT01742611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top